Li-Fraumeni syndrome: a paradigm for the understanding of hereditary cancer predisposition

British Journal of Haematology

Volumn 176, Issue 4, 2017, Pages 539-552

  Valdez, Jessica M ^a   Nichols, Kim E ^a   Kesserwan, Chimene ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

cancer predisposition; germline; Li Fraumeni syndrome; mutation; TP53

Indexed keywords

PROTEIN P53;

ADRENAL CORTEX CARCINOMA; ALLELE; BREAST CANCER; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER PREVENTION; CANCER RISK; CANCER SUSCEPTIBILITY; CANCER THERAPY; CARCINOGENICITY; CENTRAL NERVOUS SYSTEM TUMOR; GENETIC SCREENING; GENETIC VARIATION; GENOTYPE PHENOTYPE CORRELATION; GERMLINE MUTATION; HEMATOPOIETIC STEM CELL; HEREDITARY TUMOR; HUMAN; LEUKEMIA; MINIMAL RESIDUAL DISEASE; OSTEOSARCOMA; PATIENT CARE; PROTEIN FUNCTION; REVIEW; SECOND CANCER; SEX DIFFERENCE; SOFT TISSUE SARCOMA; THERAPY ASSOCIATED CANCER; TUMOR SUPPRESSOR GENE; GENETIC PREDISPOSITION; GENETICS; HEMATOLOGIC NEOPLASMS; HEMATOLOGY; LI-FRAUMENI SYNDROME; PROCEDURES; TRENDS;

GENETIC PREDISPOSITION TO DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOLOGY; HUMANS; LI-FRAUMENI SYNDROME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85012113466     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.14461     Document Type: Review

References (104)

1. Andrade, K.C., Santiago, K.M., Fortes, F.P., Mambelli, L.I., Nobrega, A.F. & Achatz, M.I. (2016) Early-onset breast cancer patients in the South and Southeast of Brazil should be tested for the TP53 p. R337H mutation. Genetics and Molecular Biology, 39, 199–202.
2. Asai, T., Liu, Y., Bae, N. & Nimer, S.D. (2011) The p53 tumor suppressor protein regulates hematopoietic stem cell fate. Journal Cell Physiology, 226, 2215–2221.
3. Baker, S.J., Fearon, E.R., Nigro, J.M., Hamilton, S.R., Preisinger, A.C., Jessup, J.M., vanTuinen, P., Ledbetter, D.H., Barker, D.F., Nakamura, Y., White, R. & Vogelstein, B. (1989) Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science, 244, 217–221.
4. Beckerman, R. & Prives, C. (2010) Transcriptional regulation by p53. Cold Spring Harbor Perspectives in Biology, 2, a000935.
5. Birch, J.M., Hartley, A.L., Tricker, K.J., Prosser, J., Condie, A., Kelsey, A.M., Harris, M., Jones, P.H., Binchy, A., Crowther, D., Craft, A.W., Eden, O.B., Evans, E.T., Mann, J.R., Martin, J., Mitchell, L.D. & Santibanez-Koref, M.F. (1994) Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families. Cancer Research, 54, 1298–1304.
6. Birch, J.M., Blair, V., Kelsey, A.M., Evans, D.G., Harris, M., Tricker, K.J. & Varley, J.M. (1998) Cancer phenotype correlates with constitutional TP53 genotype in families with the Li-Fraumeni syndrome. Oncogene, 17, 1061–1068.
7. Birch, J.M., Alston, R.D., McNally, R.J., Evans, D.G., Kelsey, A.M., Harris, M., Eden, O.B. & Varley, J.M. (2001) Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene, 20, 4621–4628.
8. Bond, G.L., Hu, W., Bond, E.E., Robins, H., Lutzker, S.G., Arva, N.C., Bargonetti, J., Bartel, F., Taubert, H., Wuerl, P., Onel, K., Yip, L., Hwang, S.J., Strong, L.C., Lozano, G. & Levine, A.J. (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 119, 591–602.
9. Bond, G.L., Hirshfield, K.M., Kirchhoff, T., Alexe, G., Bond, E.E., Robins, H., Bartel, F., Taubert, H., Wuerl, P., Hait, W., Toppmeyer, D., Offit, K. & Levine, A.J. (2006) MDM2 SNP309 accelerates tumor formation in a gender-specific and hormone-dependent manner. Cancer Research, 66, 5104–5110.
10. Bougeard, G., Baert-Desurmont, S., Tournier, I., Vasseur, S., Martin, C., Brugieres, L., Chompret, A., Bressac-de Paillerets, B., Stoppa-Lyonnet, D., Bonaiti-Pellie, C. & Frebourg, T. (2006) Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. Journal of Medical Genetics, 43, 531–533.
11. Bougeard, G., Renaux-Petel, M., Flaman, J.M., Charbonnier, C., Fermey, P., Belotti, M., Gauthier-Villars, M., Stoppa-Lyonnet, D., Consolino, E., Brugieres, L., Caron, O., Benusiglio, P.R., Bressac-de Paillerets, B., Bonadona, V., Bonaiti-Pellie, C., Tinat, J., Baert-Desurmont, S. & Frebourg, T. (2015) Revisiting Li-Fraumeni syndrome from TP53 mutation carriers. Journal of Clinical Oncology, 33, 2345–2352.
12. Boyle, J.M., Spreadborough, A., Greaves, M.J., Birch, J.M., Varley, J.M. & Scott, D. (2001) The relationship between radiation-induced G(1)arrest and chromosome aberrations in Li-Fraumeni fibroblasts with or without germline TP53 mutations. British Journal of Cancer, 85, 293–296.
13. Brosh, R. & Rotter, V. (2009) When mutants gain new powers: news from the mutant p53 field. Nature Reviews Cancer, 9, 701–713.
14. Chin, K.V., Ueda, K., Pastan, I. & Gottesman, M.M. (1992) Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science, 255, 459–462.
15. Chompret, A., Brugieres, L., Ronsin, M., Gardes, M., Dessarps-Freichey, F., Abel, A., Hua, D., Ligot, L., Dondon, M.G., Bressac-de Paillerets, B., Frebourg, T., Lemerle, J., Bonaiti-Pellie, C. & Feunteun, J. (2000) P53 germline mutations in childhood cancers and cancer risk for carrier individuals. British Journal of Cancer, 82, 1932–1937.
16. Chompret, A., Abel, A., Stoppa-Lyonnet, D., Brugieres, L., Pages, S., Feunteun, J. & Bonaiti-Pellie, C. (2001) Sensitivity and predictive value of criteria for p53 germline mutation screening. Journal Medical Genetics, 38, 43–47.
17. Churpek, J.E., Marquez, R., Neistadt, B., Claussen, K., Lee, M.K., Churpek, M.M., Huo, D., Weiner, H., Bannerjee, M., Godley, L.A., Le Beau, M.M., Pritchard, C.C., Walsh, T., King, M.C., Olopade, O.I. & Larson, R.A. (2016) Inherited mutations in cancer susceptibility genes are common among survivors of breast cancer who develop therapy-related leukemia. Cancer, 122, 304–311.
18. Custodio, G., Komechen, H., Figueiredo, F.R., Fachin, N.D., Pianovski, M.A. & Figueiredo, B.C. (2012) Molecular epidemiology of adrenocortical tumors in southern Brazil. Molecular and Cellular Endocrinology, 351, 44–51.
19. De Moura, J., Kavalec, F.L., Doghman, M., Rosati, R., Custodio, G., Lalli, E., Cavallari, G.M., Santa Maria, J. & Figueiredo, B.C. (2010) Heterozygous TP53stop146/R72P fibroblasts from a Li-Fraumeni syndrome patient with impaired response to DNA damage. International Journal of Oncology, 36, 983–990.
20. Diller, L., Sexsmith, E., Gottlieb, A., Li, F.P. & Malkin, D. (1995) Germline p53 mutations are frequently detected in young children with rhabdomyosarcoma. Journal of Clinical Investigation, 95, 1606–1611.
21. Eeles, R.A. (1995) Germline mutations in the TP53 gene. Cancer Surveys, 25, 101–124.
22. Eliyahu, D., Raz, A., Gruss, P., Givol, D. & Oren, M. (1984) Participation of p53 cellular tumour antigen in transformation of normal embryonic cells. Nature, 312, 646–649.
23. Felix, C.A., Hosler, M.R., Provisor, D., Salhany, K., Sexsmith, E.A., Slater, D.J., Cheung, N.K., Winick, N.J., Strauss, E.A., Heyn, R., Lange, B.J. & Malkin, D. (1996) The p53 gene in pediatric therapy-related leukemia and myelodysplasia. Blood, 87, 4376–4381.
24. Finlay, C.A., Hinds, P.W. & Levine, A.J. (1989) The p53 proto-oncogene can act as a suppressor of transformation. Cell, 57, 1083–1093.
25. Giacomazzi, J., Selistre, S.G., Rossi, C., Alemar, B., Santos-Silva, P., Pereira, F.S., Netto, C.B., Cossio, S.L., Roth, D.E., Brunetto, A.L., Zagonel-Oliveira, M., Martel-Planche, G., Goldim, J.R., Hainaut, P., Camey, S.A. & Ashton-Prolla, P. (2013) Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil. Cancer, 119, 4341–4349.
26. Gonzalez, K.D., Noltner, K.A., Buzin, C.H., Gu, D., Wen-Fong, C.Y., Nguyen, V.Q., Han, J.H., Lowstuter, K., Longmate, J., Sommer, S.S. & Weitzel, J.N. (2009a) Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. Journal of Clinical Oncology, 27, 1250–1256.
27. Gonzalez, K.D., Buzin, C.H., Noltner, K.A., Gu, D., Li, W., Malkin, D. & Sommer, S.S. (2009b) High frequency of de novo mutations in Li-Fraumeni syndrome. Journal of Medical Genetics, 46, 689–693.
28. Hainaut, P. & Pfeifer, G.P. (2016) Somatic TP53 mutations in the era of genome sequencing. Cold Spring Harbor Perspectives in Medicine, 6, 1–23. doi: 10.1101/cshperspect.a026179
29. Hettmer, S., Archer, N.M., Somers, G.R., Novokmet, A., Wagers, A.J., Diller, L., Rodriguez-Galindo, C., Teot, L.A. & Malkin, D. (2014) Anaplastic rhabdomyosarcoma in TP53 germline mutation carriers. Cancer, 120, 1068–1075.
30. Heymann, S., Delaloge, S., Rahal, A., Caron, O., Frebourg, T., Barreau, L., Pachet, C., Mathieu, M.C., Marsiglia, H. & Bourgier, C. (2010) Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome. Radiation Oncology, 5, 104.
31. Hisada, M., Garber, J.E., Fung, C.Y., Fraumeni, Jr, J.F. & Li, F.P. (1998) Multiple primary cancers in families with Li-Fraumeni syndrome. Journal of the National Cancer Institute, 90, 606–611.
32. Holmfeldt, L., Wei, L., Diaz-Flores, E., Walsh, M., Zhang, J., Ding, L., Payne-Turner, D., Churchman, M., Andersson, A., Chen, S.C., McCastlain, K., Becksfort, J., Ma, J., Wu, G., Patel, S.N., Heatley, S.L., Phillips, L.A., Song, G., Easton, J., Parker, M., Chen, X., Rusch, M., Boggs, K., Vadodaria, B., Hedlund, E., Drenberg, C., Baker, S., Pei, D., Cheng, C., Huether, R., Lu, C., Fulton, R.S., Fulton, L.L., Tabib, Y., Dooling, D.J., Ochoa, K., Minden, M., Lewis, I.D., To, L.B., Marlton, P., Roberts, A.W., Raca, G., Stock, W., Neale, G., Drexler, H.G., Dickins, R.A., Ellison, D.W., Shurtleff, S.A., Pui, C.H., Ribeiro, R.C., Devidas, M., Carroll, A.J., Heerema, N.A., Wood, B., Borowitz, M.J., Gastier-Foster, J.M., Raimondi, S.C., Mardis, E.R., Wilson, R.K., Downing, J.R., Hunger, S.P., Loh, M.L. & Mullighan, C.G. (2013) The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nature Genetics, 45, 242–252.
33. Id Said, B., Kim, H., Tran, J., Novokmet, A. & Malkin, D. (2016) Super-transactivation TP53 variant in the germline of a family with Li-Fraumeni syndrome. Human Mutation, 37, 889–892.
34. Kamihara, J., Rana, H.Q. & Garber, J.E. (2014) Germline TP53 mutations and the changing landscape of Li-Fraumeni syndrome. Human Mutation, 35, 654–662.
35. Kemp, C.J., Wheldon, T. & Balmain, A. (1994) p53-deficient mice are extremely susceptible to radiation-induced tumorigenesis. Nature Genetics, 8, 66–69.
36. Kleihues, P., Schauble, B., zur Hausen, A., Esteve, J. & Ohgaki, H. (1997) Tumors associated with p53 germline mutations: a synopsis of 91 families. American Journal Pathology, 150, 1–13.
37. Krutilkova, V., Trkova, M., Fleitz, J., Gregor, V., Novotna, K., Krepelova, A., Sumerauer, D., Kodet, R., Siruckova, S., Plevova, P., Bendova, S., Hedvicakova, P., Foreman, N.K. & Sedlacek, Z. (2005) Identification of five new families strengthens the link between childhood choroid plexus carcinoma and germline TP53 mutations. European Journal of Cancer, 41, 1597–1603.
38. Lammens, C.R., Aaronson, N.K., Wagner, A., Sijmons, R.H., Ausems, M.G., Vriends, A.H., Ruijs, M.W., van Os, T.A., Spruijt, L., Gomez Garcia, E.B., Kluijt, I., Nagtegaal, T., Verhoef, S. & Bleiker, E.M. (2010a) Genetic testing in Li-Fraumeni syndrome: uptake and psychosocial consequences. Journal of Clinical Oncology, 28, 3008–3014.
39. Lammens, C.R., Bleiker, E.M., Aaronson, N.K., Wagner, A., Sijmons, R.H., Ausems, M.G., Vriends, A.H., Ruijs, M.W., van Os, T.A., Spruijt, L., Gomez Garcia, E.B., Cats, A., Nagtegaal, T. & Verhoef, S. (2010b) Regular surveillance for Li-Fraumeni syndrome: advice, adherence and perceived benefits. Familial Cancer, 9, 647–654.
40. Lavigueur, A., Maltby, V., Mock, D., Rossant, J., Pawson, T. & Bernstein, A. (1989) High incidence of lung, bone, and lymphoid tumors in transgenic mice overexpressing mutant alleles of the p53 oncogene. Molecular and Cellular Biology, 9, 3982–3991.
41. Li, F.P. & Fraumeni, Jr, J.F. (1969a) Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. Journal of the National Cancer Institute, 43, 1365–1373.
42. Li, F.P. & Fraumeni, Jr, J.F. (1969b) Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Annals of Internal Medicine, 71, 747–752.
43. Li, F.P., Fraumeni, Jr, J.F., Mulvihill, J.J., Blattner, W.A., Dreyfus, M.G., Tucker, M.A. & Miller, R.W. (1988) A cancer family syndrome in twenty-four kindreds. Cancer Research, 48, 5358–5362.
44. Libe, R. & Bertherat, J. (2005) Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. European Journal of Endocrinology, 153, 477–487.
45. Liu, Y., Elf, S.E., Miyata, Y., Sashida, G., Liu, Y., Huang, G., Di Giandomenico, S., Lee, J.M., Deblasio, A., Menendez, S., Antipin, J., Reva, B., Koff, A. & Nimer, S.D. (2009) p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell, 4, 37–48.
46. Mai, P.L., Malkin, D., Garber, J.E., Schiffman, J.D., Weitzel, J.N., Strong, L.C., Wyss, O., Locke, L., Means, V., Achatz, M.I., Hainaut, P., Frebourg, T., Evans, D.G., Bleiker, E., Patenaude, A., Schneider, K., Wilfond, B., Peters, J.A., Hwang, P.M., Ford, J., Tabori, U., Ognjanovic, S., Dennis, P.A., Wentzensen, I.M., Greene, M.H., Fraumeni, Jr, J.F. & Savage, S.A. (2012) Li-Fraumeni syndrome: report of a clinical research workshop and creation of a research consortium. Cancer Genetics, 205, 479–487.
47. Mai, P.L., Best, A.F., Peters, J.A., DeCastro, R.M., Khincha, P.P., Loud, J.T., Bremer, R.C., Rosenberg, P.S. & Savage, S.A. (2016) Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort. Cancer, 205, 479–487.
48. Malkin, D. (1994) Germline p53 mutations and heritable cancer. Annual Review of Genetics, 28, 443–465.
49. Malkin, D. (2011) Li-fraumeni syndrome. Genes Cancer, 2, 475–484.
50. Malkin, D., Li, F.P., Strong, L.C., Fraumeni, Jr, J.F., Nelson, C.E., Kim, D.H., Kassel, J., Gryka, M.A., Bischoff, F.Z., Tainsky, M.A. & Friend, S.H. (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science, 250, 1233–1238.
51. Malkin, D., Nichols, K.E., Zelley, K. & Schiffman, J.D. (2014) Predisposition to pediatric and hematologic cancers: a moving target. American Society of Clinical Oncology Educational Book, 34, e44–e55.
52. Marcel, V., Palmero, E.I., Falagan-Lotsch, P., Martel-Planche, G., Ashton-Prolla, P., Olivier, M., Brentani, R.R., Hainaut, P. & Achatz, M.I. (2009) TP53 PIN3 and MDM2 SNP309 polymorphisms as genetic modifiers in the Li-Fraumeni syndrome: impact on age at first diagnosis. Journal of Medical Genetics, 46, 766–772.
53. Masciari, S., Dillon, D.A., Rath, M., Robson, M., Weitzel, J.N., Balmana, J., Gruber, S.B., Ford, J.M., Euhus, D., Lebensohn, A., Telli, M., Pochebit, S.M., Lypas, G. & Garber, J.E. (2012) Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Research and Treatment, 133, 1125–1130.
54. McBride, K.A., Ballinger, M.L., Killick, E., Kirk, J., Tattersall, M.H., Eeles, R.A., Thomas, D.M. & Mitchell, G. (2014) Li-Fraumeni syndrome: cancer risk assessment and clinical management. Nature Reviews Clinical Oncology, 11, 260–271.
55. McCuaig, J.M., Armel, S.R., Novokmet, A., Ginsburg, O.M., Demsky, R., Narod, S.A. & Malkin, D. (2012) Routine TP53 testing for breast cancer under age 30: ready for prime time? Familial Cancer, 11, 607–613.
56. Melhem-Bertrandt, A., Bojadzieva, J., Ready, K.J., Obeid, E., Liu, D.D., Gutierrez-Barrera, A.M., Litton, J.K., Olopade, O.I., Hortobagyi, G.N., Strong, L.C. & Arun, B.K. (2012) Early onset HER2-positive breast cancer is associated with germline TP53 mutations. Cancer, 118, 908–913.
57. Milner, J., Medcalf, E.A. & Cook, A.C. (1991) Tumor suppressor p53: analysis of wild-type and mutant p53 complexes. Molecular Cell Biology, 11, 12–19.
58. Mirabello, L., Yeager, M., Mai, P.L., Gastier-Foster, J.M., Gorlick, R., Khanna, C., Patino-Garcia, A., Sierrasesumaga, L., Lecanda, F., Andrulis, I.L., Wunder, J.S., Gokgoz, N., Barkauskas, D.A., Zhang, X., Vogt, A., Jones, K., Boland, J.F., Chanock, S.J. & Savage, S.A. (2015) Germline TP53 variants and susceptibility to osteosarcoma. Journal of the National Cancer Institute, 107, 1–4.
59. Moll, U.M. & Petrenko, O. (2003) The MDM2-p53 interaction. Molecular Cancer Research, 1, 1001–1008.
60. Mouchawar, J., Korch, C., Byers, T., Pitts, T.M., Li, E., McCredie, M.R., Giles, G.G., Hopper, J.L. & Southey, M.C. (2010) Population-based estimate of the contribution of TP53 mutations to subgroups of early-onset breast cancer: Australian Breast Cancer Family Study. Cancer Research, 70, 4795–4800.
61. Mullighan, C.G., Jeha, S., Pei, D., Payne-Turner, D., Coustan-Smith, E., Roberts, K.G., Waanders, E., Choi, J.K., Ma, X., Raimondi, S.C., Fan, Y., Yang, W., Song, G., Yang, J.J., Inaba, H., Downing, J.R., Leung, W.H., Bowman, W.P., Relling, M.V., Evans, W.E., Zhang, J., Campana, D. & Pui, C.H. (2015) Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels. Blood, 126, 2896–2899.
62. Nachman, J.B., Heerema, N.A., Sather, H., Camitta, B., Forestier, E., Harrison, C.J., Dastugue, N., Schrappe, M., Pui, C.H., Basso, G., Silverman, L.B. & Janka-Schaub, G.E. (2007) Outcome of treatment in children with hypodiploid acute lymphoblastic leukemia. Blood, 110, 1112–1115.
63. Nichols, K.E., Malkin, D., Garber, J.E., Fraumeni, Jr, J.F. & Li, F.P. (2001) Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiology, Biomarkers and Prevention, 10, 83–87.
64. Nigro, J.M., Baker, S.J., Preisinger, A.C., Jessup, J.M., Hostetter, R., Cleary, K., Bigner, S.H., Davidson, N., Baylin, S., Devilee, P., Glover, T., Collins, F.S., Weston, A., Modali, R., Harris, C.C. & Vogelstein, B. (1989) Mutations in the p53 gene occur in diverse human tumour types. Nature, 342, 705–708.
65. Ognjanovic, S., Olivier, M., Bergemann, T.L. & Hainaut, P. (2012) Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database. Cancer, 118, 1387–1396.
66. Olivier, M., Eeles, R., Hollstein, M., Khan, M.A., Harris, C.C. & Hainaut, P. (2002) The IARC TP53 database: new online mutation analysis and recommendations to users. Human Mutation, 19, 607–614.
67. Olivier, M., Goldgar, D.E., Sodha, N., Ohgaki, H., Kleihues, P., Hainaut, P. & Eeles, R.A. (2003) Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Research, 63, 6643–6650.
68. Palmero, E.I., Achatz, M.I., Ashton-Prolla, P., Olivier, M. & Hainaut, P. (2010) Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome. Current Opinion in Oncology, 22, 64–69.
69. Pant, V., Quintas-Cardama, A. & Lozano, G. (2012) The p53 pathway in hematopoiesis: lessons from mouse models, implications for humans. Blood, 120, 5118–5127.
70. Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S.V., Hainaut, P. & Olivier, M. (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Human Mutation, 28, 622–629.
71. Pierce, L.J. & Haffty, B.G. (2011) Radiotherapy in the treatment of hereditary breast cancer. Seminars in Radiation Oncology, 21, 43–50.
72. Pinto, E.M., Chen, X., Easton, J., Finkelstein, D., Liu, Z., Pounds, S., Rodriguez-Galindo, C., Lund, T.C., Mardis, E.R., Wilson, R.K., Boggs, K., Yergeau, D., Cheng, J., Mulder, H.L., Manne, J., Jenkins, J., Mastellaro, M.J., Figueiredo, B.C., Dyer, M.A., Pappo, A., Zhang, J., Downing, J.R., Ribeiro, R.C. & Zambetti, G.P. (2015) Genomic landscape of paediatric adrenocortical tumours. Nature Communications, 6, 6302.
73. Powell, B.C., Jiang, L., Muzny, D.M., Trevino, L.R., Dreyer, Z.E., Strong, L.C., Wheeler, D.A., Gibbs, R.A. & Plon, S.E. (2013) Identification of TP53 as an acute lymphocytic leukemia susceptibility gene through exome sequencing. Pediatric Blood & Cancer, 60, E1–E3.
74. Pui, C.H., Williams, D.L., Raimondi, S.C., Rivera, G.K., Look, A.T., Dodge, R.K., George, S.L., Behm, F.G., Crist, W.M. & Murphy, S.B. (1987) Hypodiploidy is associated with a poor prognosis in childhood acute lymphoblastic leukemia. Blood, 70, 247–253.
75. Rausch, T., Jones, D.T., Zapatka, M., Stutz, A.M., Zichner, T., Weischenfeldt, J., Jager, N., Remke, M., Shih, D., Northcott, P.A., Pfaff, E., Tica, J., Wang, Q., Massimi, L., Witt, H., Bender, S., Pleier, S., Cin, H., Hawkins, C., Beck, C., von Deimling, A., Hans, V., Brors, B., Eils, R., Scheurlen, W., Blake, J., Benes, V., Kulozik, A.E., Witt, O., Martin, D., Zhang, C., Porat, R., Merino, D.M., Wasserman, J., Jabado, N., Fontebasso, A., Bullinger, L., Rucker, F.G., Dohner, K., Dohner, H., Koster, J., Molenaar, J.J., Versteeg, R., Kool, M., Tabori, U., Malkin, D., Korshunov, A., Taylor, M.D., Lichter, P., Pfister, S.M. & Korbel, J.O. (2012) Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations. Cell, 148, 59–71.
76. Reinhardt, H.C. & Schumacher, B. (2012) The p53 network: cellular and systemic DNA damage responses in aging and cancer. Trends in Genetics, 28, 128–136.
77. Renaux-Petel, M., Sesboue, R., Baert-Desurmont, S., Vasseur, S., Fourneaux, S., Bessenay, E., Frebourg, T. & Bougeard, G. (2014) The MDM2 285G-309G haplotype is associated with an earlier age of tumour onset in patients with Li-Fraumeni syndrome. Familial Cancer, 13, 127–130.
78. Ribeiro, R.C., Michalkiewicz, E.L., Figueiredo, B.C., DeLacerda, L., Sandrini, F., Pianovsky, M.D., Sampaio, G. & Sandrini, R. (2000) Adrenocortical tumors in children. Brazilian Journal of Medical and Biological Research, 33, 1225–1234.
79. Ribeiro, R.C., Sandrini, F., Figueiredo, B., Zambetti, G.P., Michalkiewicz, E., Lafferty, A.R., DeLacerda, L., Rabin, M., Cadwell, C., Sampaio, G., Cat, I., Stratakis, C.A. & Sandrini, R. (2001) An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proceedings of the National Academy of Sciences of the United States of America, 98, 9330–9335.
80. Rodriguez-Galindo, C., Figueiredo, B.C., Zambetti, G.P. & Ribeiro, R.C. (2005) Biology, clinical characteristics, and management of adrenocortical tumors in children. Pediatric Blood Cancer, 45, 265–273.
81. Rotter, V. (1983) p53, a transformation-related cellular-encoded protein, can be used as a biochemical marker for the detection of primary mouse tumor cells. Proceedings of the National Academy of Sciences of the United States of America, 80, 2613–2617.
82. Ruijs, M.W., Schmidt, M.K., Nevanlinna, H., Tommiska, J., Aittomaki, K., Pruntel, R., Verhoef, S. & Van't Veer, L.J. (2007) The single-nucleotide polymorphism 309 in the MDM2 gene contributes to the Li-Fraumeni syndrome and related phenotypes. European Journal of Human Genetics, 15, 110–114.
83. Ruijs, M.W., Verhoef, S., Rookus, M.A., Pruntel, R., van der Hout, A.H., Hogervorst, F.B., Kluijt, I., Sijmons, R.H., Aalfs, C.M., Wagner, A., Ausems, M.G., Hoogerbrugge, N., van Asperen, C.J., Gomez Garcia, E.B., Meijers-Heijboer, H., Ten Kate, L.P., Menko, F.H. & van't Veer, L.J. (2010) TP53 germline mutation testing in 180 families suspected of Li-Fraumeni syndrome: mutation detection rate and relative frequency of cancers in different familial phenotypes. Journal of Medical Genetics, 47, 421–428.
84. Schneider, K., Zelley, K., Nichols, K.E. & Garber, J. (1993) Li-Fraumeni syndrome. In: GeneReviews(R) (ed. by R.A. Pagon, M.P. Adam, H.H. Ardinger, S.E. Wallace, A. Amemiya, L.J.H. Bean, T.D. Bird, C.T. Fong, H.C. Mefford, R.J.H. Smith & K. Stephens), University of Washington, Seattle, WA.
85. Schulz, E., Valentin, A., Ulz, P., Beham-Schmid, C., Lind, K., Rupp, V., Lackner, H., Wolfler, A., Zebisch, A., Olipitz, W., Geigl, J., Berghold, A., Speicher, M.R. & Sill, H. (2012) Germline mutations in the DNA damage response genes BRCA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms. Journal of Medical Genetics, 49, 422–428.
86. Seidinger, A.L., Fortes, F.P., Mastellaro, M.J., Cardinalli, I.A., Zambaldi, L.G., Aguiar, S.S. & Yunes, J.A. (2015) Occurrence of Neuroblastoma among TP53 p. R337H Carriers. PLoS ONE, 10, e0140356.
87. Sorrell, A.D., Espenschied, C.R., Culver, J.O. & Weitzel, J.N. (2013) Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome: current status of clinical applications and future directions. Molecular Diagnosis & Therapy, 17, 31–47.
88. Srivastava, S., Zou, Z.Q., Pirollo, K., Blattner, W. & Chang, E.H. (1990) Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature, 348, 747–749.
89. Tabori, U., Shlien, A., Baskin, B., Levitt, S., Ray, P., Alon, N., Hawkins, C., Bouffet, E., Pienkowska, M., Lafay-Cousin, L., Gozali, A., Zhukova, N., Shane, L., Gonzalez, I., Finlay, J. & Malkin, D. (2010) TP53 alterations determine clinical subgroups and survival of patients with choroid plexus tumors. Journal of Clinical Oncology, 28, 1995–2001.
90. Thull, D.L. & Vogel, V.G. (2004) Recognition and management of hereditary breast cancer syndromes. Oncologist, 9, 13–24.
91. Tinat, J., Bougeard, G., Baert-Desurmont, S., Vasseur, S., Martin, C., Bouvignies, E., Caron, O., Bressac-de Paillerets, B., Berthet, P., Dugast, C., Bonaiti-Pellie, C., Stoppa-Lyonnet, D. & Frebourg, T. (2009) 2009 version of the Chompret criteria for Li Fraumeni syndrome. Journal of Clinical Oncology, 27, e108–e109; author reply e110.
92. Varley, J.M. (2003) Germline TP53 mutations and Li-Fraumeni syndrome. Human Mutation, 21, 313–320.
93. Varley, J.M., Evans, D.G. & Birch, J.M. (1997) Li-Fraumeni syndrome – a molecular and clinical review. British Journal of Cancer, 76, 1–14.
94. Villani, A., Tabori, U., Schiffman, J., Shlien, A., Beyene, J., Druker, H., Novokmet, A., Finlay, J. & Malkin, D. (2011) Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study. Lancet Oncology, 12, 559–567.
95. Villani, A., Shore, A., Wasserman, J.D., Stephens, D., Kim, R.H., Druker, H., Gallinger, B., Naumer, A., Kohlmann, W., Novokmet, A., Tabori, U., Tijerin, M., Greer, M.C., Finlay, J.L., Schiffman, J.D. & Malkin, D. (2016) Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study. Lancet Oncology, 17, 1295–1305.
96. Vousden, K.H. & Prives, C. (2009) Blinded by the light: the growing complexity of p53. Cell, 137, 413–431.
97. Wagner, J., Portwine, C., Rabin, K., Leclerc, J.M., Narod, S.A. & Malkin, D. (1994) High frequency of germline p53 mutations in childhood adrenocortical cancer. Journal of the National Cancer Institute, 86, 1707–1710.
98. Wasserman, J.D., Novokmet, A., Eichler-Jonsson, C., Ribeiro, R.C., Rodriguez-Galindo, C., Zambetti, G.P. & Malkin, D. (2015) Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study. Journal of Clinical Oncology, 33, 602–609.
99. Willis, A., Jung, E.J., Wakefield, T. & Chen, X. (2004) Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes. Oncogene, 23, 2330–2338.
100. Wolf, D., Harris, N. & Rotter, V. (1984) Reconstitution of p53 expression in a nonproducer Ab-MuLV-transformed cell line by transfection of a functional p53 gene. Cell, 38, 119–126.
101. Wong, P., Verselis, S.J., Garber, J.E., Schneider, K., DiGianni, L., Stockwell, D.H., Li, F.P. & Syngal, S. (2006) Prevalence of early onset colorectal cancer in 397 patients with classic Li-Fraumeni syndrome. Gastroenterology, 130, 73–79.
102. Zhang, J., Walsh, M.F., Wu, G., Edmonson, M.N., Gruber, T.A., Easton, J., Hedges, D., Ma, X., Zhou, X., Yergeau, D.A., Wilkinson, M.R., Vadodaria, B., Chen, X., McGee, R.B., Hines-Dowell, S., Nuccio, R., Quinn, E., Shurtleff, S.A., Rusch, M., Patel, A., Becksfort, J.B., Wang, S., Weaver, M.S., Ding, L., Mardis, E.R., Wilson, R.K., Gajjar, A., Ellison, D.W., Pappo, A.S., Pui, C.H., Nichols, K.E. & Downing, J.R. (2015) Germline mutations in predisposition genes in pediatric cancer. New England Journal of Medicine, 373, 2336–2346.
103. Zhou, X., Edmonson, M.N., Wilkinson, M.R., Patel, A., Wu, G., Liu, Y., Li, Y., Zhang, Z., Rusch, M.C., Parker, M., Becksfort, J., Downing, J.R. & Zhang, J. (2016) Exploring genomic alteration in pediatric cancer using ProteinPaint. Nature Genetics, 48, 4–6.
104. Zhukova, N., Ramaswamy, V., Remke, M., Pfaff, E., Shih, D.J., Martin, D.C., Castelo-Branco, P., Baskin, B., Ray, P.N., Bouffet, E., von Bueren, A.O., Jones, D.T., Northcott, P.A., Kool, M., Sturm, D., Pugh, T.J., Pomeroy, S.L., Cho, Y.J., Pietsch, T., Gessi, M., Rutkowski, S., Bognar, L., Klekner, A., Cho, B.K., Kim, S.K., Wang, K.C., Eberhart, C.G., Fevre-Montange, M., Fouladi, M., French, P.J., Kros, M., Grajkowska, W.A., Gupta, N., Weiss, W.A., Hauser, P., Jabado, N., Jouvet, A., Jung, S., Kumabe, T., Lach, B., Leonard, J.R., Rubin, J.B., Liau, L.M., Massimi, L., Pollack, I.F., Shin Ra, Y., Van Meir, E.G., Zitterbart, K., Schuller, U., Hill, R.M., Lindsey, J.C., Schwalbe, E.C., Bailey, S., Ellison, D.W., Hawkins, C., Malkin, D., Clifford, S.C., Korshunov, A., Pfister, S., Taylor, M.D. & Tabori, U. (2013) Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. Journal of Clinical Oncology, 31, 2927–2935.